Author(s): Morello J, RodrguezNovoa S, JimnezNcher I, Soriano V
Abstract Share this page
Abstract Ribavirin in combination with pegylated interferon alpha is the current standard treatment for chronic hepatitis C. Adequate exposure to ribavirin seems crucial for achieving the best virological response. However, anaemia is a frequent, dose-dependent limiting side effect of ribavirin use. Therefore, therapeutic drug monitoring of ribavirin plasma concentrations could be a useful tool for individualizing ribavirin dosing. Herein, we review the relationship between ribavirin plasma concentrations and both virological response and toxicity, in order to define an optimal therapeutic range for ribavirin.
This article was published in J Antimicrob Chemother
and referenced in Journal of Clinical & Experimental Pharmacology